Free Trial

Toronto Dominion Bank Buys 3,117 Shares of Insulet Co. (NASDAQ:PODD)

Insulet logo with Medical background

Toronto Dominion Bank raised its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 15.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,502 shares of the medical instruments supplier's stock after buying an additional 3,117 shares during the period. Toronto Dominion Bank's holdings in Insulet were worth $5,470,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Baillie Gifford & Co. increased its stake in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock worth $529,669,000 after purchasing an additional 389,639 shares in the last quarter. Geode Capital Management LLC grew its holdings in Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock valued at $403,339,000 after purchasing an additional 22,850 shares during the period. Clearbridge Investments LLC increased its position in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier's stock worth $270,364,000 after buying an additional 75,526 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Insulet by 18.7% in the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier's stock worth $178,728,000 after buying an additional 139,246 shares during the period. Finally, Westfield Capital Management Co. LP raised its stake in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock worth $175,697,000 after buying an additional 163,388 shares during the period.

Insulet Price Performance

Shares of NASDAQ:PODD traded down $2.39 during mid-day trading on Friday, reaching $269.34. The stock had a trading volume of 571,633 shares, compared to its average volume of 538,081. The business's 50 day moving average price is $251.37 and its 200 day moving average price is $220.65. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a market cap of $18.89 billion, a P/E ratio of 46.12, a price-to-earnings-growth ratio of 4.12 and a beta of 1.21. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insiders Place Their Bets

In other news, CAO Lauren Budden sold 915 shares of the company's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.47% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PODD. Raymond James boosted their price objective on Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research note on Monday, October 14th. JPMorgan Chase & Co. upped their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research report on Thursday. Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price objective for the company. Piper Sandler lifted their target price on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Finally, BTIG Research increased their price target on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus price target of $267.44.

View Our Latest Stock Analysis on PODD

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Recommended Stories

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Should you invest $1,000 in Insulet right now?

Before you consider Insulet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.

While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines